title: Rheumatic carditis treated with high doses of pulsetherapy methylprednisolone. Results in 70 children over 12 years.
abstract: OBJECTIVE
  To report the result of patients treated with IV methylprednisolone divided into three groups and compare their follow-up during the last 12 years.
  
  
  METHODS
  Seventy children with active rheumatic carditis (76 episodes) in heart failure Class III and IV (NYHA) were studied. The diagnosis was based on modified Jones' criteria. After ruling out infections and strongyloidiasis, treatment with IV methylprednisolone bolus was started three times a week until the laboratory tests became negative. Patients were divided into 3 groups, according to the time of hospital admittance: Groups 1, 2 and 3, comprising of 40, 18 and 12 children, respectively.
  
  
  RESULTS
  Eighteen children in Group 1 (45%) were in their 1st attack: 2 series of pulsetherapy were used in 10 (25%), 3 in 9 (23%) and 4 in 21 (52%). In Group 2, 14 cases (77%) were in their 1st attack: 2 series were used in 7 (39%), 4 in 9 (50%) and 5 in 2 (11%). The echocardiogram showed a flail mitral valve in 12 (66%) of these patients (1 death occurred after mitral valvoplasty). In Group 3, 6 patients needed 5 or more series of pulsetherapy and a flail mitral valve was present in 5 (41%). One child underwent mitral valve replacement while still in the active phase, after 8 series of pulsetherapy, and another died. The number of patients who needed 5 or more series was significantly higher in Group 3.
  
  
  CONCLUSIONS
  There were variations in the presentation and evolution of the cases during these 12 year. The established pulsetherapy protocol continues to be useful to treat severe cases.
authors.affiliation: Hospital Universitário Antônio Pedro-UFF, Brazil.
authors.forename: G V
authors.initials: GV
authors.lastname: Herdy
authors.forename: C A
authors.initials: CA
authors.lastname: Pinto
authors.forename: M C
authors.initials: MC
authors.lastname: Olivaes
authors.forename: E A
authors.initials: EA
authors.lastname: Carvalho
authors.forename: H
authors.initials: H
authors.lastname: Tchou
authors.forename: R
authors.initials: R
authors.lastname: Cosendey
authors.forename: R
authors.initials: R
authors.lastname: Ribeiro
authors.forename: F
authors.initials: F
authors.lastname: Azeredo
authors.forename: D
authors.initials: D
authors.lastname: de Souza
authors.forename: A H
authors.initials: AH
authors.lastname: Herdy
authors.forename: V G
authors.initials: VG
authors.lastname: Lopes
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007275:Injections, Intravenous; D008775:Methylprednisolone / Q000627:therapeutic use*; D009205:Myocarditis / Q000188:drug therapy*; D011446:Prospective Studies; D012214:Rheumatic Heart Disease / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone